MDS Pharma Services
Lincoln, Nebraska, 68502, United States
NCT Number: NCT00619931
The APD791-002 study is designed primarily to evaluate the safety, tolerability, and pharmacokinetics of APD791 when administered for 7 days to healthy adult subjects.
Looking for future studies?
Notify Me19 year–45 year
All sexes
Interventional
Phase 1
Lincoln, Nebraska, 68502, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
APD791 or matching placebo in escalating doses
Time frame: Throughout study duration
Time frame: Throughout study duration
Time frame: Throughout study duration
Arena Pharmaceuticals
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07232732
Body Weight, Healthy
Daytona Beach, Florida, United States
View Trial DetailsNCT07781618
Healthy
Bruges, West-Flanders, Belgium
View Trial DetailsNCT04606979
Basal Ganglia Diseases, Brain Diseases
Brussels, Brussels Capital, Belgium
View Trial DetailsNCT05804344
Healthy
New York, United States
View Trial Details